• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过自由能微扰和伞形采样研究间变性淋巴瘤激酶的L1196M突变诱导的构象变化及耐药机制

Mutation L1196M-induced conformational changes and the drug resistant mechanism of anaplastic lymphoma kinase studied by free energy perturbation and umbrella sampling.

作者信息

Chen Jianzhong, Wang Jinan, Zhu Weiliang

机构信息

School of Science, Shandong Jiaotong University, Jinan, 250014, China.

出版信息

Phys Chem Chem Phys. 2017 Nov 15;19(44):30239-30248. doi: 10.1039/c7cp05418a.

DOI:10.1039/c7cp05418a
PMID:29109998
Abstract

Anaplastic lymphoma kinase (ALK) has been regarded as a promising drug target in the treatment of tumors and the mutation L1196M induces different levels of drug resistance toward the existing inhibitors. Free energy perturbation (FEP) coupled with umbrella sampling simulation is used to investigate the conformational change of ALK induced by L1196M and drug-resistant mechanisms of L1196M on four inhibitors VGH, 3U9, 5P8 and IV7. Dynamics analysis shows that L119M produces significant influences on the flexibility of the loops L1 and L2 in ALK. FEP calculations suggest that the drug-resistant intensity of L1196M toward inhibitors decreases in the order 3U9 > VGH > 5P8 > IV7, in accordance with the experimentally determined results. Moreover, statistical analysis of hydrophobic contacts of inhibitors with separate residues in ALK further demonstrates that the decrease in the hydrophobic interactions of inhibitors with L1256 mostly drives drug resistance of L1196M toward inhibitors. The calculations of potential of mean force (PMF) based on umbrella sampling simulations indicate that the free energies of inhibitor-L1196M ALKs are lower than those of inhibitor-wild ALKs. This study is expected to provide significant theoretical support which would help in the design of potent inhibitors alleviating the drug resistance of L1196M in ALK.

摘要

间变性淋巴瘤激酶(ALK)被视为肿瘤治疗中一个有前景的药物靶点,而L1196M突变会对现有抑制剂产生不同程度的耐药性。采用自由能微扰(FEP)结合伞形采样模拟来研究L1196M诱导的ALK构象变化以及L1196M对四种抑制剂VGH、3U9、5P8和IV7的耐药机制。动力学分析表明,L119M对ALK中L1和L2环的灵活性产生显著影响。FEP计算表明,L1196M对抑制剂的耐药强度按3U9 > VGH > 5P8 > IV7的顺序降低,这与实验测定结果一致。此外,对抑制剂与ALK中单个残基的疏水接触进行统计分析进一步表明,抑制剂与L1256疏水相互作用的降低主要导致L1196M对抑制剂产生耐药性。基于伞形采样模拟的平均力势(PMF)计算表明,抑制剂-L1196M-ALK的自由能低于抑制剂-野生型-ALK的自由能。本研究有望提供重要的理论支持,有助于设计强效抑制剂以减轻ALK中L1196M的耐药性。

相似文献

1
Mutation L1196M-induced conformational changes and the drug resistant mechanism of anaplastic lymphoma kinase studied by free energy perturbation and umbrella sampling.通过自由能微扰和伞形采样研究间变性淋巴瘤激酶的L1196M突变诱导的构象变化及耐药机制
Phys Chem Chem Phys. 2017 Nov 15;19(44):30239-30248. doi: 10.1039/c7cp05418a.
2
In-depth theoretical modeling to explore the mechanism of TPX-0131 overcoming lorlatinib resistance to ALK mutation.深入的理论建模探索 TPX-0131 克服 ALK 突变对 lorlatinib 耐药的机制。
Comput Biol Med. 2024 Dec;183:109265. doi: 10.1016/j.compbiomed.2024.109265. Epub 2024 Oct 15.
3
Mutation-mediated influences on binding of anaplastic lymphoma kinase to crizotinib decoded by multiple replica Gaussian accelerated molecular dynamics.多重复制高斯加速分子动力学解码间变性淋巴瘤激酶与克唑替尼结合的突变介导影响。
J Comput Aided Mol Des. 2020 Dec;34(12):1289-1305. doi: 10.1007/s10822-020-00355-5. Epub 2020 Oct 19.
4
Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer.通过计算揭示色瑞替尼如何克服ALK重排肺癌中的耐药突变。
J Mol Model. 2015 Jul;21(7):175. doi: 10.1007/s00894-015-2716-z. Epub 2015 Jun 18.
5
Molecular Mechanism Behind the Resistance of the G1202R-Mutated Anaplastic Lymphoma Kinase to the Approved Drug Ceritinib.G1202R 突变型间变性淋巴瘤激酶对已批准药物色瑞替尼耐药的分子机制。
J Phys Chem B. 2018 May 3;122(17):4680-4692. doi: 10.1021/acs.jpcb.8b02040. Epub 2018 Apr 24.
6
Identification of 1-pyrazolo[3,4-b]pyridine derivatives as potent ALK-L1196M inhibitors.鉴定 1-吡唑并[3,4-b]吡啶衍生物作为有效的 ALK-L1196M 抑制剂。
J Enzyme Inhib Med Chem. 2019 Dec;34(1):1426-1438. doi: 10.1080/14756366.2019.1639694.
7
Discovery of Low Micromolar Dual Inhibitors for Wild Type and L1196M Mutant of Anaplastic Lymphoma Kinase through Structure-Based Virtual Screening.通过基于结构的虚拟筛选发现间变性淋巴瘤激酶野生型和L1196M突变体的低微摩尔双抑制剂
J Chem Inf Model. 2016 Apr 25;56(4):802-10. doi: 10.1021/acs.jcim.6b00026. Epub 2016 Apr 4.
8
Drug-resistance mechanisms of three mutations in anaplastic lymphoma kinase against two inhibitors based on MM/PBSA combined with interaction entropy.基于 MM/PBSA 结合相互作用熵的三种间变性淋巴瘤激酶突变体对两种抑制剂的耐药机制。
Phys Chem Chem Phys. 2019 Oct 7;21(37):20951-20964. doi: 10.1039/c9cp02851j. Epub 2019 Sep 16.
9
Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1.针对一种口服可用的间变性淋巴瘤激酶和c-Ros癌基因1新型抑制剂的转化药代动力学-药效学建模。
J Pharmacol Exp Ther. 2014 Oct;351(1):67-76. doi: 10.1124/jpet.114.217141. Epub 2014 Jul 29.
10
An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer.ALK阳性非小细胞肺癌中,小分子激酶抑制剂与间变性淋巴瘤激酶(ALK)突变体的相互作用图谱。
Biochimie. 2015 May;112:111-20. doi: 10.1016/j.biochi.2015.03.003. Epub 2015 Mar 11.

引用本文的文献

1
Searching for potential acetylcholinesterase inhibitors: a combined approach of multi-step similarity search, machine learning and molecular dynamics simulations.寻找潜在的乙酰胆碱酯酶抑制剂:多步相似性搜索、机器学习和分子动力学模拟的联合方法
R Soc Open Sci. 2024 Oct 2;11(10):240546. doi: 10.1098/rsos.240546. eCollection 2024 Oct.
2
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.NVL-655是一种对多种ALK突变癌蛋白具有选择性且能穿透血脑屏障的抑制剂,包括对劳拉替尼耐药的复合突变。
Cancer Discov. 2024 Dec 2;14(12):2367-2386. doi: 10.1158/2159-8290.CD-24-0231.
3
Imidazole[1,5-a]pyridine derivatives as EGFR tyrosine kinase inhibitors unraveled by umbrella sampling and steered molecular dynamics simulations.
咪唑并[1,5-a]吡啶衍生物作为 EGFR 酪氨酸激酶抑制剂的揭示:伞状采样和导向分子动力学模拟。
Sci Rep. 2024 May 28;14(1):12218. doi: 10.1038/s41598-024-62743-3.
4
A computational examination of the therapeutic advantages of fourth-generation ALK inhibitors TPX-0131 and repotrectinib over third-generation lorlatinib for NSCLC with ALK F1174C/L/V mutations.对第四代ALK抑制剂TPX-0131和瑞波替尼相较于第三代劳拉替尼治疗具有ALK F1174C/L/V突变的非小细胞肺癌的治疗优势的计算研究。
Front Mol Biosci. 2024 Jan 11;10:1306046. doi: 10.3389/fmolb.2023.1306046. eCollection 2023.
5
Comparative Atomistic Insights on Apo and ATP-I1171N/S/T in Nonsmall-Cell Lung Cancer.非小细胞肺癌中脱辅基蛋白及ATP-I1171N/S/T的比较原子水平见解
ACS Omega. 2023 Nov 6;8(46):43856-43872. doi: 10.1021/acsomega.3c05785. eCollection 2023 Nov 21.
6
Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer.治疗非小细胞肺癌中罕见 ALK 融合的新进展。
Curr Oncol. 2022 Oct 16;29(10):7816-7831. doi: 10.3390/curroncol29100618.
7
Efflux dynamics of the antiseizure drug, levetiracetam, through the P-glycoprotein channel revealed by advanced comparative molecular simulations.先进的比较分子模拟揭示抗癫痫药物左乙拉西坦通过 P-糖蛋白通道的外排动力学。
Sci Rep. 2022 Aug 11;12(1):13674. doi: 10.1038/s41598-022-17994-3.
8
Exploring the binding mechanisms of PDE5 with chromeno[2,3-]pyrrol-9(2)-one by theoretical approaches.通过理论方法探索磷酸二酯酶5(PDE5)与色烯并[2,3 - ]吡咯 - 9(2)-酮的结合机制。
RSC Adv. 2018 Aug 29;8(53):30481-30490. doi: 10.1039/c8ra06405a. eCollection 2018 Aug 24.
9
Dynamics revelation of conformational changes and binding modes of heat shock protein 90 induced by inhibitor associations.抑制剂结合诱导的热休克蛋白90构象变化和结合模式的动力学揭示
RSC Adv. 2018 Jul 16;8(45):25456-25467. doi: 10.1039/c8ra05042b.
10
Experimental and Computational Study on the Microfluidic Control of Micellar Nanocarrier Properties.胶束纳米载体性质的微流体控制实验与计算研究
ACS Omega. 2021 Aug 30;6(36):23117-23128. doi: 10.1021/acsomega.1c02651. eCollection 2021 Sep 14.